Saturday, June 29 Evaluation

Question Title

* 1. Please select your designation(s):

PhD

Other (please specify)

Question Title

* 2. Please indicate your specialties:

Allergy

Asthma

Autoimmunity

Cell Biology

Dermatology

Diabetes

Endocrinology

Flow Cytometry

Gastroenterology

Genetics

Hematology

Infectious Disease

Inflammation

Microbiology

Molecular & Cellular Biology

Multiple Sclerosis

Neuroimmunology

Neurology

Oncology

Pathology

Pharmacology

Primary Immuno-deficiency

Rheumatology

Transplantation

Uveitis

Question Title

* 3. Please select the categories you most identify with:

Trainee/Fellow

Industry

Academic Faculty

Clinician

Question Title

* 4. Saturday, June 29, 8:00-9:45am
Plenary Session: Measuring Antigen Specific Responses

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice as a result of what I learned in this session.	I will make changes in my practice as a result of what I learned in this session. Disagree	I will make changes in my practice as a result of what I learned in this session. Undecided	I will make changes in my practice as a result of what I learned in this session. Agree	I will make changes in my practice as a result of what I learned in this session. Did not attend

Question Title

* 5. After participating in this session, are you able to:

	Yes	No
Apply approaches for detection of rare cells involved in human immune disease pathogenesis	Apply approaches for detection of rare cells involved in human immune disease pathogenesis Yes	Apply approaches for detection of rare cells involved in human immune disease pathogenesis No
Restate that with improvements in peptide-MHC tetramer technology, we can now directly characterize specific T cells prior to any infection or stimulation in the pre-immune repertoire	Restate that with improvements in peptide-MHC tetramer technology, we can now directly characterize specific T cells prior to any infection or stimulation in the pre-immune repertoire Yes	Restate that with improvements in peptide-MHC tetramer technology, we can now directly characterize specific T cells prior to any infection or stimulation in the pre-immune repertoire No
Contrast that in adults, but not newborns, there is an abundance of memory phenotype T cells in unexposed individuals, which may explain the susceptiblity of young children to infectious diseases	Contrast that in adults, but not newborns, there is an abundance of memory phenotype T cells in unexposed individuals, which may explain the susceptiblity of young children to infectious diseases Yes	Contrast that in adults, but not newborns, there is an abundance of memory phenotype T cells in unexposed individuals, which may explain the susceptiblity of young children to infectious diseases No
Report how the Immune Epitope Database and Analysis Resource (IEDB), originally developed to focus on infectious disease data, can be used to analyze epitope data related to autoimmunity	Report how the Immune Epitope Database and Analysis Resource (IEDB), originally developed to focus on infectious disease data, can be used to analyze epitope data related to autoimmunity Yes	Report how the Immune Epitope Database and Analysis Resource (IEDB), originally developed to focus on infectious disease data, can be used to analyze epitope data related to autoimmunity No
Examine how common questions related to diabetes epitopes can be answered using the IEDB and the results of the queries.	Examine how common questions related to diabetes epitopes can be answered using the IEDB and the results of the queries. Yes	Examine how common questions related to diabetes epitopes can be answered using the IEDB and the results of the queries. No

Question Title

* 6. Please rate the quality of the presentations:

	Excellent	Good	Average	Poor
Biomarkers & Beyond - Jerry Nepom, MD, PhD	Biomarkers & Beyond - Jerry Nepom, MD, PhD Excellent	Biomarkers & Beyond - Jerry Nepom, MD, PhD Good	Biomarkers & Beyond - Jerry Nepom, MD, PhD Average	Biomarkers & Beyond - Jerry Nepom, MD, PhD Poor
The Human T Cell Receptor Repertoire: Implications for Autoimmunity and Infectious Disease - Mark Davis, PhD	The Human T Cell Receptor Repertoire: Implications for Autoimmunity and Infectious Disease - Mark Davis, PhD Excellent	The Human T Cell Receptor Repertoire: Implications for Autoimmunity and Infectious Disease - Mark Davis, PhD Good	The Human T Cell Receptor Repertoire: Implications for Autoimmunity and Infectious Disease - Mark Davis, PhD Average	The Human T Cell Receptor Repertoire: Implications for Autoimmunity and Infectious Disease - Mark Davis, PhD Poor
The Use of the Immune Eiptope Database (IEDB) to Study Autoimmune Epitope Data - Alessandro Sette, PhD	The Use of the Immune Eiptope Database (IEDB) to Study Autoimmune Epitope Data - Alessandro Sette, PhD Excellent	The Use of the Immune Eiptope Database (IEDB) to Study Autoimmune Epitope Data - Alessandro Sette, PhD Good	The Use of the Immune Eiptope Database (IEDB) to Study Autoimmune Epitope Data - Alessandro Sette, PhD Average	The Use of the Immune Eiptope Database (IEDB) to Study Autoimmune Epitope Data - Alessandro Sette, PhD Poor

Comments

Question Title

* 7. Did you perceive bias in any of the session presentations?

	Yes	No
Biomarkers & Beyond - Jerry Nepom, MD, PhD	Biomarkers & Beyond - Jerry Nepom, MD, PhD Yes	Biomarkers & Beyond - Jerry Nepom, MD, PhD No
The Human T Cell Receptor Repertoire: Implications for Autoimmunity and Infectious Diseases - Mark Davis, PhD	The Human T Cell Receptor Repertoire: Implications for Autoimmunity and Infectious Diseases - Mark Davis, PhD Yes	The Human T Cell Receptor Repertoire: Implications for Autoimmunity and Infectious Diseases - Mark Davis, PhD No
The Use of the Immune Epitope Database (IEDB) to Study Autoimmune Epitope Data - Alessandro Setto, PhD	The Use of the Immune Epitope Database (IEDB) to Study Autoimmune Epitope Data - Alessandro Setto, PhD Yes	The Use of the Immune Epitope Database (IEDB) to Study Autoimmune Epitope Data - Alessandro Setto, PhD No

If yes, please specify

Question Title

* 8. Saturday, June 29, 10:00-11:45 am
Plenary Session: Mechanistic Basis for Targeted Therapies

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 9. After participating in this session, are you able to:

	Yes	No
Describe the novel regulatory pathways that promote the pathogenesis of rheumatoid arthritis	Describe the novel regulatory pathways that promote the pathogenesis of rheumatoid arthritis Yes	Describe the novel regulatory pathways that promote the pathogenesis of rheumatoid arthritis No
Distinguish the diversity of dendritic cells and T cell subsets in active skin lesions	Distinguish the diversity of dendritic cells and T cell subsets in active skin lesions Yes	Distinguish the diversity of dendritic cells and T cell subsets in active skin lesions No
Contrast the different effector pathways and cytokine effects of Th1 versus Th17 cell subsets on epidermal keratinocytes	Contrast the different effector pathways and cytokine effects of Th1 versus Th17 cell subsets on epidermal keratinocytes Yes	Contrast the different effector pathways and cytokine effects of Th1 versus Th17 cell subsets on epidermal keratinocytes No
Discuss emerging data that suggests the central pathogenic pathway psoriasis is IL-23 regulated Th17 (IL17) driven and that there is a strong interaction of this pathway with TNF	Discuss emerging data that suggests the central pathogenic pathway psoriasis is IL-23 regulated Th17 (IL17) driven and that there is a strong interaction of this pathway with TNF Yes	Discuss emerging data that suggests the central pathogenic pathway psoriasis is IL-23 regulated Th17 (IL17) driven and that there is a strong interaction of this pathway with TNF No

Question Title

* 10. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
Novel Regulatory Pathways in Rheumatoid Arthritis - Towards New Therapeutics - Iain McInnes, MD, PhD	Novel Regulatory Pathways in Rheumatoid Arthritis - Towards New Therapeutics - Iain McInnes, MD, PhD Excellent	Novel Regulatory Pathways in Rheumatoid Arthritis - Towards New Therapeutics - Iain McInnes, MD, PhD Good	Novel Regulatory Pathways in Rheumatoid Arthritis - Towards New Therapeutics - Iain McInnes, MD, PhD Average	Novel Regulatory Pathways in Rheumatoid Arthritis - Towards New Therapeutics - Iain McInnes, MD, PhD Poor
Pathogenic Cytokine Circuits in Psoriasis - James Krueger, MD, PhD	Pathogenic Cytokine Circuits in Psoriasis - James Krueger, MD, PhD Excellent	Pathogenic Cytokine Circuits in Psoriasis - James Krueger, MD, PhD Good	Pathogenic Cytokine Circuits in Psoriasis - James Krueger, MD, PhD Average	Pathogenic Cytokine Circuits in Psoriasis - James Krueger, MD, PhD Poor
Novel Pathogenic Roles for Interferon and Autoantibodies in Human SLE - Virginia Pascual, MD	Novel Pathogenic Roles for Interferon and Autoantibodies in Human SLE - Virginia Pascual, MD Excellent	Novel Pathogenic Roles for Interferon and Autoantibodies in Human SLE - Virginia Pascual, MD Good	Novel Pathogenic Roles for Interferon and Autoantibodies in Human SLE - Virginia Pascual, MD Average	Novel Pathogenic Roles for Interferon and Autoantibodies in Human SLE - Virginia Pascual, MD Poor

Comments

Question Title

* 11. Did you perceive bias in any of the session presentations?

	Yes	No
Novel Regulatory Pathways in Rheumatoid Arthritis - Towards New Therapeutics - Iain McInnes, MD, PhD	Novel Regulatory Pathways in Rheumatoid Arthritis - Towards New Therapeutics - Iain McInnes, MD, PhD Yes	Novel Regulatory Pathways in Rheumatoid Arthritis - Towards New Therapeutics - Iain McInnes, MD, PhD No
Pathogenic Cytokine Circuits in Psoriasis - James Krueger, MD, PhD	Pathogenic Cytokine Circuits in Psoriasis - James Krueger, MD, PhD Yes	Pathogenic Cytokine Circuits in Psoriasis - James Krueger, MD, PhD No
Novel Pathogenic Roles for Interferon and Autoantibodies in Human SLE - Virginia Pascual, MD	Novel Pathogenic Roles for Interferon and Autoantibodies in Human SLE - Virginia Pascual, MD Yes	Novel Pathogenic Roles for Interferon and Autoantibodies in Human SLE - Virginia Pascual, MD No

If yes, please specify

Question Title

* 12. Saturday, June 29, 1:15-3:00 pm
Concurrent Thematic Symposium: Nucleic Sensing and Immune Responses

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 13. After participating in this session, are you able to:

	Yes	No
Explain cell-intrinsic mechanisms of antiviral resistance and how they can, when dysregulated, contribute to autoimmune disease	Explain cell-intrinsic mechanisms of antiviral resistance and how they can, when dysregulated, contribute to autoimmune disease Yes	Explain cell-intrinsic mechanisms of antiviral resistance and how they can, when dysregulated, contribute to autoimmune disease No
Restate that innate immune sensors that defect foreign DNA are important for defense against DNA viruses, invasive bacteria and infectious retroviruses	Restate that innate immune sensors that defect foreign DNA are important for defense against DNA viruses, invasive bacteria and infectious retroviruses Yes	Restate that innate immune sensors that defect foreign DNA are important for defense against DNA viruses, invasive bacteria and infectious retroviruses No
Describe recent work that has found that the endogenous retroelements that comprise 40% of the human genome can also generate reverse-transcribed cDNAs that are detected by the same sensors, leading to autoimmune disease	Describe recent work that has found that the endogenous retroelements that comprise 40% of the human genome can also generate reverse-transcribed cDNAs that are detected by the same sensors, leading to autoimmune disease Yes	Describe recent work that has found that the endogenous retroelements that comprise 40% of the human genome can also generate reverse-transcribed cDNAs that are detected by the same sensors, leading to autoimmune disease No
Identify the types of nucleic acids that are recognized by Toll-like receptors	Identify the types of nucleic acids that are recognized by Toll-like receptors Yes	Identify the types of nucleic acids that are recognized by Toll-like receptors No
Describe the effect of nucleic acid modifications on immune stimulation	Describe the effect of nucleic acid modifications on immune stimulation Yes	Describe the effect of nucleic acid modifications on immune stimulation No

Question Title

* 14. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
Cell-intrinsic Detection of Viral Nucleic Acids - Caetano Reis e Sousa, DPhil	Cell-intrinsic Detection of Viral Nucleic Acids - Caetano Reis e Sousa, DPhil Excellent	Cell-intrinsic Detection of Viral Nucleic Acids - Caetano Reis e Sousa, DPhil Good	Cell-intrinsic Detection of Viral Nucleic Acids - Caetano Reis e Sousa, DPhil Average	Cell-intrinsic Detection of Viral Nucleic Acids - Caetano Reis e Sousa, DPhil Poor
Endogenous Retroelements and Autoimmunity - Daniel Stetson, PhD	Endogenous Retroelements and Autoimmunity - Daniel Stetson, PhD Excellent	Endogenous Retroelements and Autoimmunity - Daniel Stetson, PhD Good	Endogenous Retroelements and Autoimmunity - Daniel Stetson, PhD Average	Endogenous Retroelements and Autoimmunity - Daniel Stetson, PhD Poor
The Innate Immune Response to Malaria is Due to the Recognition of DNA - Douglas Golenbock, MD	The Innate Immune Response to Malaria is Due to the Recognition of DNA - Douglas Golenbock, MD Excellent	The Innate Immune Response to Malaria is Due to the Recognition of DNA - Douglas Golenbock, MD Good	The Innate Immune Response to Malaria is Due to the Recognition of DNA - Douglas Golenbock, MD Average	The Innate Immune Response to Malaria is Due to the Recognition of DNA - Douglas Golenbock, MD Poor

Comments

Question Title

* 15. Did you perceive bias in any of the session presentations?

	Yes	No
Cell-intrinsic Detection of Viral Nucleic Acids - Caetano Reis e Sousa, DPhil	Cell-intrinsic Detection of Viral Nucleic Acids - Caetano Reis e Sousa, DPhil Yes	Cell-intrinsic Detection of Viral Nucleic Acids - Caetano Reis e Sousa, DPhil No
Endogenous Retroelements and Autoimmunity - Daniel Stetson, PhD	Endogenous Retroelements and Autoimmunity - Daniel Stetson, PhD Yes	Endogenous Retroelements and Autoimmunity - Daniel Stetson, PhD No
The Innate Immune Response to Malaria is Due to the Recognition of DNA - Douglas Golenbock, MD	The Innate Immune Response to Malaria is Due to the Recognition of DNA - Douglas Golenbock, MD Yes	The Innate Immune Response to Malaria is Due to the Recognition of DNA - Douglas Golenbock, MD No

If yes, please specify

Question Title

* 16. Saturday, June 29 1:15-3:00 pm
Concurrent Thematic Symposium: T Cell Memory versus Exhaustion

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 17. After participating in this session, are you able to:

	Yes	No
Describe the cellular and molecular difference between an exhausted and a tolerant state	Describe the cellular and molecular difference between an exhausted and a tolerant state Yes	Describe the cellular and molecular difference between an exhausted and a tolerant state No
Explain the epigenetic regulation that maintains CD8 T cells in a tolerant state	Explain the epigenetic regulation that maintains CD8 T cells in a tolerant state Yes	Explain the epigenetic regulation that maintains CD8 T cells in a tolerant state No
Cite that T cells are capable of 'sterilizing' and curing widely metastatic cancer	Cite that T cells are capable of 'sterilizing' and curing widely metastatic cancer Yes	Cite that T cells are capable of 'sterilizing' and curing widely metastatic cancer No
Explore the molecular and metabolic control of T cell differentiation, senescence and death	Explore the molecular and metabolic control of T cell differentiation, senescence and death Yes	Explore the molecular and metabolic control of T cell differentiation, senescence and death No
Identify the distinguishing features of memory exhausted and senescent T cells	Identify the distinguishing features of memory exhausted and senescent T cells Yes	Identify the distinguishing features of memory exhausted and senescent T cells No
Describe the functional consequences of these distinct phenotypes	Describe the functional consequences of these distinct phenotypes Yes	Describe the functional consequences of these distinct phenotypes No

Question Title

* 18. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
CD8 T Cell Exhaustion versus Tolerance: The Transition from a Cell-extrinsic Fate - Phil Greenberg, MD	CD8 T Cell Exhaustion versus Tolerance: The Transition from a Cell-extrinsic Fate - Phil Greenberg, MD Excellent	CD8 T Cell Exhaustion versus Tolerance: The Transition from a Cell-extrinsic Fate - Phil Greenberg, MD Good	CD8 T Cell Exhaustion versus Tolerance: The Transition from a Cell-extrinsic Fate - Phil Greenberg, MD Average	CD8 T Cell Exhaustion versus Tolerance: The Transition from a Cell-extrinsic Fate - Phil Greenberg, MD Poor
Metabolic and Molecular Control of T Cell Differentiation, Senescence and Death - Nick Restifo, MD	Metabolic and Molecular Control of T Cell Differentiation, Senescence and Death - Nick Restifo, MD Excellent	Metabolic and Molecular Control of T Cell Differentiation, Senescence and Death - Nick Restifo, MD Good	Metabolic and Molecular Control of T Cell Differentiation, Senescence and Death - Nick Restifo, MD Average	Metabolic and Molecular Control of T Cell Differentiation, Senescence and Death - Nick Restifo, MD Poor
T Cell Memory and Exhaustion - Allan Kirk, MD, PhD	T Cell Memory and Exhaustion - Allan Kirk, MD, PhD Excellent	T Cell Memory and Exhaustion - Allan Kirk, MD, PhD Good	T Cell Memory and Exhaustion - Allan Kirk, MD, PhD Average	T Cell Memory and Exhaustion - Allan Kirk, MD, PhD Poor

Comments

Question Title

* 19. Did you perceive bias in any of the session presentations?

	Yes	No
CD8 T Cell Exhaustion versus Tolerance: The Transition from a Cell-extrinsic Fate - Phil Greenberg, MD	CD8 T Cell Exhaustion versus Tolerance: The Transition from a Cell-extrinsic Fate - Phil Greenberg, MD Yes	CD8 T Cell Exhaustion versus Tolerance: The Transition from a Cell-extrinsic Fate - Phil Greenberg, MD No
Metabolic and Molecular Control of T Cell Differentiation, Senescence and Death - Nick Restifo, MD	Metabolic and Molecular Control of T Cell Differentiation, Senescence and Death - Nick Restifo, MD Yes	Metabolic and Molecular Control of T Cell Differentiation, Senescence and Death - Nick Restifo, MD No
T Cell Memory and Exhaustion - Allan Kirk, MD, PhD	T Cell Memory and Exhaustion - Allan Kirk, MD, PhD Yes	T Cell Memory and Exhaustion - Allan Kirk, MD, PhD No

If yes, please specify

Question Title

* 20. Saturday, Jun 29, 1:15-3:00 pm
Concurrent Thematic Symposium: Microbiome and Immune Development

	Disagree	Undecided	Agree	Did not attend
I will make changes to my practice/profession as a result of what I learned in this session.	I will make changes to my practice/profession as a result of what I learned in this session. Disagree	I will make changes to my practice/profession as a result of what I learned in this session. Undecided	I will make changes to my practice/profession as a result of what I learned in this session. Agree	I will make changes to my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 21. After participating in this session, are you able to:

	Yes	No
Discuss the gut microbiome and its role in autoimmunity, in particular central nervous system demyelination	Discuss the gut microbiome and its role in autoimmunity, in particular central nervous system demyelination Yes	Discuss the gut microbiome and its role in autoimmunity, in particular central nervous system demyelination No
Discuss the role of commensals in the control of immunity to pathogens in the gut and the skin	Discuss the role of commensals in the control of immunity to pathogens in the gut and the skin Yes	Discuss the role of commensals in the control of immunity to pathogens in the gut and the skin No
Restate mechanisms that microbiota uses to control autoimmunity and inflammation	Restate mechanisms that microbiota uses to control autoimmunity and inflammation Yes	Restate mechanisms that microbiota uses to control autoimmunity and inflammation No

Question Title

* 22. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
The Gut Microbiome and Regulation in CNS Demyelinating Disease - Lloyd Kasper, MD	The Gut Microbiome and Regulation in CNS Demyelinating Disease - Lloyd Kasper, MD Excellent	The Gut Microbiome and Regulation in CNS Demyelinating Disease - Lloyd Kasper, MD Good	The Gut Microbiome and Regulation in CNS Demyelinating Disease - Lloyd Kasper, MD Average	The Gut Microbiome and Regulation in CNS Demyelinating Disease - Lloyd Kasper, MD Poor
Compartmentalized Control of Tissue Immunity by Commensals - Yasmine Belkaid, PhD	Compartmentalized Control of Tissue Immunity by Commensals - Yasmine Belkaid, PhD Excellent	Compartmentalized Control of Tissue Immunity by Commensals - Yasmine Belkaid, PhD Good	Compartmentalized Control of Tissue Immunity by Commensals - Yasmine Belkaid, PhD Average	Compartmentalized Control of Tissue Immunity by Commensals - Yasmine Belkaid, PhD Poor
Intestinal Microbiota in Immunity and Autoimmunity - Alexander Chervonsky, MD, PhD	Intestinal Microbiota in Immunity and Autoimmunity - Alexander Chervonsky, MD, PhD Excellent	Intestinal Microbiota in Immunity and Autoimmunity - Alexander Chervonsky, MD, PhD Good	Intestinal Microbiota in Immunity and Autoimmunity - Alexander Chervonsky, MD, PhD Average	Intestinal Microbiota in Immunity and Autoimmunity - Alexander Chervonsky, MD, PhD Poor

Comments

Question Title

* 23. Did you perceive bias in any of the session presentations?

	Yes	No
The Gut Microbiome and Regulation in CNS Demyelinating Disease - Lloyd Kasper, MD	The Gut Microbiome and Regulation in CNS Demyelinating Disease - Lloyd Kasper, MD Yes	The Gut Microbiome and Regulation in CNS Demyelinating Disease - Lloyd Kasper, MD No
Compartmentalized Control of Tissue Immunity by Commensals - Yasmine Belkaid, PhD	Compartmentalized Control of Tissue Immunity by Commensals - Yasmine Belkaid, PhD Yes	Compartmentalized Control of Tissue Immunity by Commensals - Yasmine Belkaid, PhD No
Intestinal Microbiota in Immunity and Autoimmunity - Alexander Chervonsky, MD, PhD	Intestinal Microbiota in Immunity and Autoimmunity - Alexander Chervonsky, MD, PhD Yes	Intestinal Microbiota in Immunity and Autoimmunity - Alexander Chervonsky, MD, PhD No

If yes, please specify

Question Title

* 24. Saturday, June 29, 3:15-5:15 pm
Featured Course: Principles of Flow Cytometry for Immune Monitoring Part II

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 25. After participating in this session, are you able to:

	Yes	No
Compare and contrast the applications best suited for imaging and mass cytometry	Compare and contrast the applications best suited for imaging and mass cytometry Yes	Compare and contrast the applications best suited for imaging and mass cytometry No
Discuss the current limitations of each of these technologies	Discuss the current limitations of each of these technologies Yes	Discuss the current limitations of each of these technologies No

Question Title

* 26. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
Imaging Cytometry - J. Philip McCoy, PhD	Imaging Cytometry - J. Philip McCoy, PhD Excellent	Imaging Cytometry - J. Philip McCoy, PhD Good	Imaging Cytometry - J. Philip McCoy, PhD Average	Imaging Cytometry - J. Philip McCoy, PhD Poor
Mass Cytometry (CyTOF) - Holden Maecker, PhD	Mass Cytometry (CyTOF) - Holden Maecker, PhD Excellent	Mass Cytometry (CyTOF) - Holden Maecker, PhD Good	Mass Cytometry (CyTOF) - Holden Maecker, PhD Average	Mass Cytometry (CyTOF) - Holden Maecker, PhD Poor

Comments

Question Title

* 27. Did you perceive bias in any of the session presentations?

	Yes	No
Imaging Cytometry - J. Philip McCoy, PhD	Imaging Cytometry - J. Philip McCoy, PhD Yes	Imaging Cytometry - J. Philip McCoy, PhD No
Mass Cytometry (CyTOF) - Holden Maecker, PhD	Mass Cytometry (CyTOF) - Holden Maecker, PhD Yes	Mass Cytometry (CyTOF) - Holden Maecker, PhD No

If yes, please specify

Question Title

* 28. Saturday, June 29, 5:30-6:30 pm
Presidential Keynote Address: Controlling Autoimmunity: The Effector T Cell Balance - Abul Abbas, MD

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 29. After participating in this session, are you able to:

	Yes	No
Differentiate between effectory and regulatory T cells and their roles in autoimmune diseases	Differentiate between effectory and regulatory T cells and their roles in autoimmune diseases Yes	Differentiate between effectory and regulatory T cells and their roles in autoimmune diseases No
Explain the roles of the cytokine IL-12 in immune responses and inflammatory diseases	Explain the roles of the cytokine IL-12 in immune responses and inflammatory diseases Yes	Explain the roles of the cytokine IL-12 in immune responses and inflammatory diseases No
Apply how these concepts develop new therapies	Apply how these concepts develop new therapies Yes	Apply how these concepts develop new therapies No

Question Title

* 30. Please rate the quality of this presentation.

Excellent

Good

Average

Poor

Comments

Question Title

* 31. Did you perceive bias in this presentation?

Yes

If yes, please specify

Question Title

* 32. If you would like to receive a CME certificate or certificate of attendance, please indicate below.

CME Certificate

Certificate of Attendance

Please enter your email to receive a certificate

Question Title

* 1. Please select your designation(s):

Question Title

* 2. Please indicate your specialties:

Question Title

* 3. Please select the categories you most identify with:

Question Title

* 4. Saturday, June 29, 8:00-9:45amPlenary Session: Measuring Antigen Specific Responses

Question Title

* 5. After participating in this session, are you able to:

Question Title

* 6. Please rate the quality of the presentations:

Question Title

* 7. Did you perceive bias in any of the session presentations?

Question Title

* 8. Saturday, June 29, 10:00-11:45 amPlenary Session: Mechanistic Basis for Targeted Therapies

Question Title

* 9. After participating in this session, are you able to:

Question Title

* 10. Please rate the quality of the session presentations:

Question Title

* 11. Did you perceive bias in any of the session presentations?

Question Title

* 12. Saturday, June 29, 1:15-3:00 pmConcurrent Thematic Symposium: Nucleic Sensing and Immune Responses

Question Title

* 13. After participating in this session, are you able to:

Question Title

* 14. Please rate the quality of the session presentations:

Question Title

* 15. Did you perceive bias in any of the session presentations?

Question Title

* 16. Saturday, June 29 1:15-3:00 pmConcurrent Thematic Symposium: T Cell Memory versus Exhaustion

Question Title

* 17. After participating in this session, are you able to:

Question Title

* 18. Please rate the quality of the session presentations:

Question Title

* 19. Did you perceive bias in any of the session presentations?

Question Title

* 20. Saturday, Jun 29, 1:15-3:00 pmConcurrent Thematic Symposium: Microbiome and Immune Development

Question Title

* 21. After participating in this session, are you able to:

Question Title

* 22. Please rate the quality of the session presentations:

Question Title

* 23. Did you perceive bias in any of the session presentations?

Question Title

* 24. Saturday, June 29, 3:15-5:15 pmFeatured Course: Principles of Flow Cytometry for Immune Monitoring Part II

Question Title

* 25. After participating in this session, are you able to:

Question Title

* 26. Please rate the quality of the session presentations:

Question Title

* 27. Did you perceive bias in any of the session presentations?

Question Title

* 28. Saturday, June 29, 5:30-6:30 pm Presidential Keynote Address: Controlling Autoimmunity: The Effector T Cell Balance - Abul Abbas, MD

Question Title

* 29. After participating in this session, are you able to:

Question Title

* 30. Please rate the quality of this presentation.

Question Title

* 31. Did you perceive bias in this presentation?

Question Title

* 32. If you would like to receive a CME certificate or certificate of attendance, please indicate below.

* 4. Saturday, June 29, 8:00-9:45am
Plenary Session: Measuring Antigen Specific Responses

* 8. Saturday, June 29, 10:00-11:45 am
Plenary Session: Mechanistic Basis for Targeted Therapies

* 12. Saturday, June 29, 1:15-3:00 pm
Concurrent Thematic Symposium: Nucleic Sensing and Immune Responses

* 16. Saturday, June 29 1:15-3:00 pm
Concurrent Thematic Symposium: T Cell Memory versus Exhaustion

* 20. Saturday, Jun 29, 1:15-3:00 pm
Concurrent Thematic Symposium: Microbiome and Immune Development

* 24. Saturday, June 29, 3:15-5:15 pm
Featured Course: Principles of Flow Cytometry for Immune Monitoring Part II

* 28. Saturday, June 29, 5:30-6:30 pm
Presidential Keynote Address: Controlling Autoimmunity: The Effector T Cell Balance - Abul Abbas, MD